retatrutide ly3437943 triple agonist glp-1 gip glucagon mechanism (LY3437943): of Action and Research Overview Retatrutide online: complete guide to

Growing physician awareness of the cardiovascular and metabolic benefits of GLP-1 receptor agonists continues to accelerate adoption across endocrinology, primary care, and obesity medicine

ADA guidance also notes benefits of GLP-1 RAs in diabetes patients who also have cardiovascular disease, chronic kidney disease, or obesity-linked complications

[4] The theoretical benefits of combining allulose with GLP-1 therapy centre on enhanced glycaemic control and weight management

ISSN 0092-8674

This is in line with the fact that, although some studies have shown the presence of the GLP-1R in other parts of the heart (Wei and Mojsov, 1995

Preclinical studies have clearly demonstrated that GLP-1RAs effectively reduce hepatic macrophage infiltration and suppress expression of TNF- , IL-6, and other pro-inflammatory mediators in animal models of MASLD (21, 22)